• On 29 July 2026, Lausanne University Hospital (CHUV) announced a multi-year research collaboration with 10x Genomics to use its Flex Apex, Xenium and planned Atera platforms to study tumor samples from hundreds of advanced cancer patients and explore single cell and spatial technologies alongside standard-of-care assays.
• The project aims to integrate rich molecular data with clinical outcomes to uncover biomarkers that could inform future diagnostic frameworks, treatment selection and molecular tumor board decisions across several major solid tumor types.
• We’ll now examine how this CHUV collaboration, particularly its focus on clinically actionable oncology biomarkers using 10x’s platforms, influences 10x Genomics’ investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

10x Genomics Investment Narrative Recap

To own 10x Genomics, you need to believe single cell and spatial biology will keep attracting research and clinical budgets despite funding pressures and ongoing losses. The CHUV collaboration strengthens the clinical relevance of 10x’s platforms, but it does not obviously change the near term picture where softer academic spending, lower average selling prices and the path back to profitability remain the key catalyst and the central risk.

Among recent updates, the April 2026 unveiling of the Atera spatial biology platform fits closely with the CHUV news, as CHUV plans to expand its study onto Atera. Together, Atera’s whole transcriptome spatial capabilities and these multi year oncology collaborations highlight how new products and clinical grade datasets could influence future demand for 10x’s instruments, consumables and software, even as current revenue growth and margins remain under pressure.

Yet while collaborations like CHUV hint at long term potential, investors should also be aware that...

10x Genomics' narrative projects $709.8 million revenue and $110.2 million earnings by 2029. This requires 3.4% yearly revenue growth and a $153.7 million earnings increase from -$43.5 million today.

Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 57% downside to its current price.

Exploring Other Perspectives

Compared with the consensus view, the most optimistic analysts expect revenue to reach about US$828 million by 2029 and still highlight biopharma and AI driven workflows as powerful offsets to funding risk. Before the CHUV news, they already framed faster consumables growth and new clinical applications as reasons the story could surprise to the upside, so this type of cancer collaboration may prompt you to revisit whether their assumptions still feel too optimistic or perhaps closer to your own expectations.

Explore 3 other fair value estimates on 10x Genomics - why the stock might be worth as much as 83% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 48 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.